Acute Functional Rescue: Can MitoQ Improve Mobility in Peripheral Artery Disease?
Written by Georgia Truman (MSc), Molecular and Cellular Biology. Reviewed by Dr. Siobhan Mitchell (PhD), Neuroscience.
Peripheral Artery Disease (PAD) is a devastating cardiovascular condition where plaque buildup in the leg arteries restricts blood flow, leading to chronic claudication (pain during movement). This restricted flow causes ischemia-reperfusion cycles that damage mitochondria, leading to high levels of oxidative stress and severely limited mobility.
What you’ll learn:
Changes in maximal walking time and distance after a single 80mg dose of Mitoquinol.
Impact on popliteal and brachial artery flow-mediated dilation (FMD).
MitoQ's effect on endogenous Superoxide Dismutase (SOD) activity.
How does MitoQ affect exercise tolerance and claudication onset?
In this crossover trial, 11 patients with PAD took a single 80mg dose of MitoQ. Participants experienced an immediate increase in maximal walking time by 74 seconds (P<0.001) and walking distance by 49 meters (P=0.012). Most importantly for the patient experience, the claudication onset time (COT) was delayed, allowing them to walk significantly longer before the pain forced them to stop.
What were the vascular and biomarker outcomes observed?
Supplementation significantly improved popliteal artery FMD (increasing from 2.7% to 6.0%) and brachial artery FMD. These vascular gains were supported by a significant increase in the activity of the body's internal defense enzyme, Superoxide Dismutase (SOD), which rose from 0.37 to 0.40 U/mL (P<0.01).
What does this mean for practitioners managing PAD?
The ability of an acute dose to "unmask" vascular capacity suggests that MitoQ could be used as a "pre-therapy" tool to help patients tolerate longer and more intense walking rehabilitation programs. While long-term chronic studies are needed, these results indicate that targeting mitochondrial stress can acutely improve both the "plumbing" and the functional performance of the lower limbs.
DOI: 10.1152/ajpheart.00235.2020
